Form 4: REGENXBIO CEO Sells Shares Under 10b5-1 Plan

REGENXBIO Inc.'s CEO, Curran Simpson, sold 7,734 shares of common stock for a weighted average price of $10.02 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Curran Simpson, Chief Executive Officer and Director of REGENXBIO Inc., sold 7,734 shares of the company's common stock.
• The transaction took place on September 10, 2025.
• The shares were sold at a weighted average price of $10.02 per share, with individual trades ranging from $10.00 to $10.07.
• This sale was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following this transaction, Mr. Simpson directly beneficially owns 244,597 shares of REGENXBIO common stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is an insider sale, which can be viewed negatively, but it was executed under a pre-arranged 10b5-1 plan, mitigating concerns about opportunistic timing. It's a routine disclosure for an executive managing their personal holdings.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a discretionary sale based on immediate market conditions or new information.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake and can sometimes be perceived negatively by the market, though the 10b5-1 plan mitigates concerns about opportunistic timing.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan mitigates immediate concerns about management's view of future prospects.

Key Dates

Recommendation

The filing details a routine insider sale executed under a Rule 10b5-1 plan, which is a pre-scheduled transaction. This type of sale does not typically indicate a change in the company's fundamental outlook or management's confidence. Therefore, it provides no new information that would warrant a change in investment thesis, suggesting a 'hold' recommendation based solely on this filing.

Keywords

REGENXBIO, RGNX, Insider Trading, Form 4, Stock Sale, CEO, Curran Simpson, 10b5-1 Plan, Biotechnology, Gene Therapy